MAPK1 and lung cancer: High cytoplasmic RAP1 can increase cisplatin resistance of NSCLC combined with increased NF-κB activity (Xiao et al., 2017), and RAS-RAF-MEK-ERK signaling was a vital pathway that mediates ALK positive tumor cell survival in lung cancer (Hrustanovic and Bivona, 2016).